

See <u>Web Announcement 2587</u> for instructions on billing additional COVID-19 doses.

August 20, 2021
Web Announcement 2566

Attention Provider Type 28 (Pharmacy):

Amendment to Vaccine Administration Reimbursement for Additional Doses of Moderna and Pfizer COVID-19 Vaccines

On August 12, 2021, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUA) for both the Pfizer and Moderna COVID-19 vaccinations. This EUA allows for a third dose to be administered at least 28 days following the two-dose regimen of the same vaccine to immunocompromised recipients. The additional dose applies to immunocompromised recipients 18 years of age or older for the Moderna vaccination and ages 12 or older for the Pfizer vaccination. *It does not apply to recipients that are not immunocompromised.*

Effective August 18, 2021, Nevada Medicaid will pay a vaccine administration fee of \$40.44 to Point-of-Sale (POS) pharmacy providers for a third dose of the Pfizer and Moderna COVID-19 vaccines for Fee-for-Service Medicaid recipients that meet criteria for medical necessity. Additional reimbursement for vaccine administration is extended to recipients that are immunocompromised due to solid organ transplant or recipients that are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. Examples include but are not limited to cancer, human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS) and inherited diseases that affect the immune system. POS claims must include the National Drug Code (NDC) from the same manufacturer that was used with previous doses.

Refer to Nevada Medicaid and Nevada Check Up Pharmacy Manual for additional billing guidance at: https://www.medicaid.nv.gov/Downloads/provider/NV Pharmacy Manual.pdf